Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Gary Schiller"'
Autor:
Amir Fathi, Eunice Wang, Ghayas Issa, Jessica Altman, Pau Montesinos, Stéphane de Botton, Roland Walter, Kirsten Pettit, Mrinal Patnaik, Marina Kremyanskaya, Maria Baer, James M Foran, Gary Schiller, Lionel Ades, Maël Heiblig, Pierre Peterlin, Olga Salamero Garcia, Cristina Papayannidis, Kun Nie, Julie Ahsan Mackey, Marilyn Tabachri, Daniel Corum, Mollie Leoni, Stephen Dale, Harry Erba
Publikováno v:
HemaSphere, Vol 7, p e19161da (2023)
Externí odkaz:
https://doaj.org/article/8e09726e3c94452db7d4ebd57a3010e3
Autor:
Ellen Ritchie, Tara L. Lin, Laura F. Newell, Robert K. Stuart, Scott Solomon, Richard Stone, Gary Schiller, Matthew Wieduwilt, Eileen Amy Ryan, Nalina Dronamraju, Jeffrey Lancet, Jorge Cortes
Publikováno v:
HemaSphere, Vol 7, p e7753968 (2023)
Externí odkaz:
https://doaj.org/article/adfffa9e836c4f858b031d7da2a6b267
Publikováno v:
HemaSphere, Vol 7, p e14426d1 (2023)
Externí odkaz:
https://doaj.org/article/22c84fd0cbb84c468f2a2fd015e33b38
Autor:
Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous, Jesus Berdeja, Jesse Shustik, Gary Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald Quick, Bertrand Anz, Gustavo Fonseca, Unicel-Anne Flores, Hongjuan Liu, Christian Gentili, David Siegel
Publikováno v:
HemaSphere, Vol 7, p e757660c (2023)
Externí odkaz:
https://doaj.org/article/09a1c2116ed7488a999443b855f5ac3d
Autor:
Anand Patel, Laura Michaelis, Gary Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon Bray, Elizabeth A. Olek, Richard Cutler, Jorge Dimartino, Eytan Stein
Publikováno v:
HemaSphere, Vol 7, p e1492994 (2023)
Externí odkaz:
https://doaj.org/article/0fcdebe12f7f4ca5b2f0a3bf48e1eb43
Autor:
Darrell White, Muhamed Baljevic, Gary Schiller, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane Van Domelen, Ohad Bentur, Sumit Madan
Publikováno v:
HemaSphere, Vol 7, p e899038f (2023)
Externí odkaz:
https://doaj.org/article/b8ad9ccb9a8741008a6b591a95cc73d4
Autor:
Nicolas Boissel, Patrice Chevallier, Kevin Curran, Gary Schiller, Hongtau Liu, Richard Larson, Daniel J. Deangelo, Jean-Baptiste Mear, Stephan Grupp, André Baruchel, Marina Konopleva, Alexandra Lacroce, Caroline Roudet, Ana Korngold, Katie Newhall, Eric Laille, Daniel Lee, Mark Frattini, Nitin Jain
Publikováno v:
HemaSphere, Vol 7, p e323373f (2023)
Externí odkaz:
https://doaj.org/article/d1b05a402662471f84abd44475913a2c
Autor:
Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma
Externí odkaz:
https://doaj.org/article/ad0d07b841e64c82afc2fcdee19751cf
Autor:
Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, Muhamed Baljevic, William Bensinger, Richard LeBlanc, Chris Venner, Nizar Bahlis, Adriana Rossi, Noa Biran, Heidi Sheehan, Jean‐Richard Saint‐Martin, Dane Van Domelen, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 56-65 (2021)
Abstract We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination
Externí odkaz:
https://doaj.org/article/69e08a3b96d24bf1a3690cc152ca6a6b
Publikováno v:
Leukemia Research Reports, Vol 9, Iss , Pp 65-71 (2018)
Although rare, secondary clonal hematologic neoplasia may occur after successful therapy for acute promyelocytic leukemia (APL). These secondary clonal events may be considered therapy-related, but may also be due to an underlying background of clona
Externí odkaz:
https://doaj.org/article/48fd6088661741c1afd69a371703d7ff